Review

Worldwide Sternal Closure Systems Industry to 2026 - Insights, Competitive Landscape and Market Forecasts - ResearchAndMarkets.com

Thursday, September 23, 2021 - 10:05am

Additionally, an all-inclusive account of the currently available Sternal Closure Systems is provided, which will have an impact on the future market of Sternal Closure Systems.

Key Points: 
  • Additionally, an all-inclusive account of the currently available Sternal Closure Systems is provided, which will have an impact on the future market of Sternal Closure Systems.
  • A detailed review of Sternal Closure Systems market; historical and forecasted market size is included in the report, covering devices outreach in the 7MM.
  • The report provides an edge while developing business strategies, by understanding trends shaping and driving the Sternal Closure Systems market.
  • The report helps in developing business strategies by understanding trends shaping and driving the Sternal Closure Systems market.

Diadem Announces New Publication Reviewing How Post Translational Modifications of p53 Variants May Contribute to Development of Alzheimer's Disease

Thursday, September 23, 2021 - 7:00am

Increasing evidence suggests that certain conformational variants and post-translational modifications of p53, well known for its role in cancer, may significantly impact the development of AD.

Key Points: 
  • Increasing evidence suggests that certain conformational variants and post-translational modifications of p53, well known for its role in cancer, may significantly impact the development of AD.
  • This knowledge is already fueling creation of novel prognostic tests for AD and may lead to the development of new therapies to counter disease progression."
  • p53 is involved in the regulation of oxidative stress, which is implicated as one of the earliest events in AD.
  • Diadem is preparing for rapid commercialization of its initial Alzheimer's prognostic via a global launch in collaboration with strategic partners.

Number of Shares and Voting Rights of Innate Pharma as of September 1, 2021

Thursday, September 23, 2021 - 6:00am

Disclaimer on forward-looking information and risk factors:

Key Points: 
  • Disclaimer on forward-looking information and risk factors:
    This press release contains certain forward-looking statements, including those within the meaning of the Private Securities Litigation Reform Act of 1995.The use of certain words, including believe, potential, expect and will and similar expressions, is intended to identify forward-looking statements.
  • Although the company believes its expectations are based on reasonable assumptions, these forward-looking statements are subject to numerous risks and uncertainties, which could cause actual results to differ materially from those anticipated.
  • These risks and uncertainties include, among other things, the uncertainties inherent in research and development, including related to safety, progression of and results from its ongoing and planned clinical trials and preclinical studies, review and approvals by regulatory authorities of its product candidates, the Companys commercialization efforts, the Companys continued ability to raise capital to fund its development and the overall impact of the COVID-19 outbreak on the global healthcare system as well as the Companys business, financial condition and results of operations.
  • This press release and the information contained herein do not constitute an offer to sell or a solicitation of an offer to buy or subscribe to shares in Innate Pharma in any country.

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Iterum, View, and Spectrum and Encourages Investors to Contact the Firm

Thursday, September 23, 2021 - 2:07am

On this news, Iterums ordinary share price fell $0.87 per share, or 37.99%, to close at $1.42 per share on July 2, 2021.

Key Points: 
  • On this news, Iterums ordinary share price fell $0.87 per share, or 37.99%, to close at $1.42 per share on July 2, 2021.
  • On this news, Iterums ordinary share price fell $0.499 per share, or 44.16%, to close at $0.631 per share on July 26, 2021.
  • For more information on the Spectrum class action go to: https://bespc.com/cases/SPPI
    About Bragar Eagel & Squire, P.C.
  • The firm represents individual and institutional investors in commercial, securities, derivative, and other complex litigation in state and federal courts across the country.

Nexus REIT Announces Q3 2021 Results Date and September 2021 Distribution

Thursday, September 23, 2021 - 12:00am

TORONTO and MONTREAL, Sept. 22, 2021 (GLOBE NEWSWIRE) -- Nexus Real Estate Investment Trust (TSX: NXR.UN) (Nexus or the REIT) announced today that it intends to release its financial results for the third quarter ended September30, 2021 before the opening of the TSX on Monday November 15, 2021.

Key Points: 
  • TORONTO and MONTREAL, Sept. 22, 2021 (GLOBE NEWSWIRE) -- Nexus Real Estate Investment Trust (TSX: NXR.UN) (Nexus or the REIT) announced today that it intends to release its financial results for the third quarter ended September30, 2021 before the opening of the TSX on Monday November 15, 2021.
  • Management of the REIT will host a conference call at 1:00 PM Eastern Standard Time on Monday November15, 2021 to review the financial results and operations.
  • The REITs distribution reinvestment plan (DRIP) entitles eligible unitholders to elect to receive all, or a portion of the cash distributions of the REIT reinvested in units of the REIT.
  • Eligible unitholders who so elect will receive a bonus distribution of units equal to 4% of each distribution that was reinvested by them under the DRIP.

Axonics® Provides Additional Update on Inter Partes Review Proceedings

Wednesday, September 22, 2021 - 11:08pm

In March 2020, Axonics filed petitions with the PTAB requesting inter partes review (IPR) to contest the validity of patents Medtronic has alleged to be infringed by Axonics.

Key Points: 
  • In March 2020, Axonics filed petitions with the PTAB requesting inter partes review (IPR) to contest the validity of patents Medtronic has alleged to be infringed by Axonics.
  • In September 2020, the PTAB granted Axonics request and instituted a review of the six Medtronic patents.
  • Today, the PTAB issued its decision on the three remaining Medtronic patents Axonics is contesting: Patent Nos.
  • Except as required by law, Axonics undertakes no obligation to update or revise any forward-looking statements to reflect new information, changed circumstances or unanticipated events.

FSD Pharma Announces Engagement with Capital Markets Communications Providers and Market Maker

Wednesday, September 22, 2021 - 11:30pm

Management has made this decision following a thorough review of capital on hand and allocated these resources to investor relations.

Key Points: 
  • Management has made this decision following a thorough review of capital on hand and allocated these resources to investor relations.
  • North Equities' engagement is for a term of seven months (contract signed July 23, 2021).
  • The FSD Shares will be subject to the statutory hold period of four months and one day.
  • KCSA, a leading New York City-based communications firm, has been engaged month to month to develop strategic communications.

InvestorBrandNetwork Announces M.A.D. Casters Interview with TAAT™ Global Alternatives Inc. CEO Setti Coscarella

Wednesday, September 22, 2021 - 10:57pm

During the interview, Coscarella provided insight into his professional background before discussing TAATs unique approach to giving tobacco smokers the choice to leave nicotine behind while keeping the experiences they love.

Key Points: 
  • During the interview, Coscarella provided insight into his professional background before discussing TAATs unique approach to giving tobacco smokers the choice to leave nicotine behind while keeping the experiences they love.
  • From there, I went on to private equity and spent quite a bit of time working on green energy products, Coscarella said.
  • The company has developed TAAT, which is a tobacco-free and nicotine-free alternative to traditional cigarettes offered in Original, Smooth, and Menthol varieties.
  • These risks and uncertainties could cause the company's actual results to differ materially from those indicated in the forward-looking statements.

Wabash National Announces Pricing of Notes Offering

Wednesday, September 22, 2021 - 9:59pm

LAFAYETTE, Ind., Sept. 22, 2021 (GLOBE NEWSWIRE) -- Wabash National Corporation (NYSE: WNC) today announced the pricing of its previously announced private offering of $400 million aggregate principal amount of senior unsecured notes due 2028 (the Notes).

Key Points: 
  • LAFAYETTE, Ind., Sept. 22, 2021 (GLOBE NEWSWIRE) -- Wabash National Corporation (NYSE: WNC) today announced the pricing of its previously announced private offering of $400 million aggregate principal amount of senior unsecured notes due 2028 (the Notes).
  • The closing of the Notes offering is expected to occur on October 6, 2021, subject to customary closing conditions.
  • The Notes will be guaranteed on a senior unsecured basis by certain of Wabash Nationals domestic subsidiaries.
  • Its innovative products are sold under the following brand names: Wabash National, Benson, Brenner Tank, Bulk Tank International, DuraPlate, Supreme, Transcraft, Walker Engineered Products, and Walker Transport.

ITRM SHAREHOLDER CLASS ACTION DEADLINE: Bernstein Liebhard LLP Reminds Investors of the Deadline to File a Lead Plaintiff Motion in a Securities Class Action Lawsuit Against Iterum Therapeutics plc

Wednesday, September 22, 2021 - 9:40pm

The lawsuit filed in the United States District Court for the Northern District of Illinois alleges violations of the Exchange Act of 1934.

Key Points: 
  • The lawsuit filed in the United States District Court for the Northern District of Illinois alleges violations of the Exchange Act of 1934.
  • If you wish to serve as lead plaintiff, you must move the Court no later than October 4, 2021.
  • A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.
  • The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, (212) 779-1414.